ISBN: 978-83-60043-10-3 - eurobic9

B. Meunier
Eurobic9, 2-6 September, 2008, Wrocław, Poland
KL24. Alzheimer Disease: a Bioinorganic Approach
PALUMED, rue Pierre et Marie Curie, BP 28262, 31682 Labège cedex.
Among the (unresolved) questions in the pathophysiology of different neurodegenerative diseases, including
Alzheimer’s disease (AD), one concerns the role of metal ions (zinc, copper and iron) in the formation of
amyloid plaques. Two of these metal ions are redox-active and are able to generate reactive oxygen species
(ROS, mainly hydrogen peroxide and hydroxyl radicals) that can create irreversible damage on neurons.
Since these metal ions are in large excess in the brain of AD patients, the development of a selective chelatotherapy
is a possible strategy to treate AD. Such approach has been initially developed by A. Bush and coll. by
using clioquinol, an old antibiotic able to chelate copper ions (1).
In Toulouse, we have recently developed two different series of new chelating agents (2) that might have a future
in the treatment of neurodegenerative diseases (3-6).
References
[1] Cherny et al., Neuron, 2001, 30, 665.
[2] Two patents pending (PALUMED-CNRS, 2003 and 2005).
[3] C. Boldron, I. Van der Auwera, C. Deraeve, H. Gornitzka, S. Wera, M. Pitié, F. van Leuven, B. Meunier,
ChemBioChem, 2005, 6, 1976.
[4] C. Deraeve, M. Pitié, B. Meunier, J. Inorg. Chem. 2006, 100, 2117.
[5] C. Deraeve, M. Pitié, H. Mazarguil, B. Meunier, New J. Chem. 2007, 31, 193.
[6] C. Deraeve, C. Boldron, A. Maraval, H. Mazarguil, H. Gornitza, L. Vendier, M. Pitié, B. Meunier, Chemistry,
2008, 14, 682.
_____________________________________________________________________
43